Pomalidomide (Pomalyst)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Second-generation immunomodulatory drug (IMiD)--a thalidomide analogue--with antineoplastic activity. Pomalidomide has been shown to inhibit growth and induce apoptosis of hematopoietic tumor cells, enhance natural killer (NK) and T-cell cell-mediated immunity, and suppress monocyte production of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).[1][2][3]

Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Clinical trials

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: CC4047, CC-4047
  • Generic name: 3-amino-thalidomide
  • Brand names: Actimid, Ibipolid, Imnovid, Pomalid, Pomalyst


  1. 1.0 1.1 1.2 1.3 Pomalidomide (Pomalyst) package insert
  2. Pomalidomide (Pomalyst)‎ package insert (locally hosted backup)
  3. Pomalyst manufacturer's website
  4. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article PubMed
  5. Meletios A. Dimopoulos, MD, Martha Q Lacy, MD, Philippe Moreau, MD, Katja C Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Anne Banos, MD, Albert Oriol, MD, Xin Yu, PhD, Lars Sternas, MD, Christian J. Jacques, MD, Mohamed Zaki, MD and Jesús F San Miguel, MD, PhD. Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. 2012 ASH Annual Meeting abstract LBA-6. link to abstract
  6. Pomalidomide (Pomalyst) patient drug information (Chemocare)
  7. Pomalidomide (Pomalyst) patient drug information (UpToDate)